The cost of Invokana 100 mg can vary depending on insurance coverage, pharmacy, and geographic location. Without insurance, a prescription for Invokana 100 mg typically costs around $500 to $600 for a 30-day supply [1].
What influences the price of Invokana?
Several factors can affect the out-of-pocket cost for Invokana 100 mg. These include the specific pharmacy where the prescription is filled, whether a generic version is available and approved, and the terms of a patient's insurance plan, such as their deductible, copay, and coinsurance [1]. Manufacturer coupons or savings cards can also reduce the cost for eligible individuals [1].
Are there cheaper alternatives to Invokana?
Invokana (canagliflozin) is a brand-name medication. While a generic version may become available in the future, it is not currently approved [2]. Other medications within the SGLT2 inhibitor class, such as Jardiance (empagliflozin) and Farxiga (dapagliflozin), are available and may have different pricing structures [3]. Treatment decisions should always be made in consultation with a healthcare provider.
When does the patent for Invokana expire?
The patent protection for Invokana is complex and involves multiple patents covering the drug substance, methods of use, and formulations. According to DrugPatentWatch.com, the earliest expected patent expiry date for canagliflozin is around late 2026, with later patents extending further [4]. The exact timeline for when generic versions could be available depends on patent challenges and regulatory approvals.
How can I find out about Invokana savings programs?
Patients interested in reducing the cost of Invokana can explore savings options offered by the manufacturer. These may include discount cards or patient assistance programs designed to lower out-of-pocket expenses for eligible individuals [1]. Checking the official Invokana website or inquiring at the pharmacy are common ways to find information on these programs.
What is Invokana used for?
Invokana is prescribed to improve blood sugar control in adults with type 2 diabetes. It is also used to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria [5].
---
Sources:
[1] https://www.goodrx.com/invokana
[2] https://www.drugpatentwatch.com/drug/canagliflozin
[3] https://www.webmd.com/drugs/2/drug-167006/invokana-oral
[4] https://www.drugpatentwatch.com/drug/canagliflozin
[5] https://www.invokana.com/